US EditionDepression spray to be cheaper for Aussie patients
- A new nasal spray called Spravato has been added to Australia's Pharmaceutical Benefits Scheme for adults with treatment-resistant depression, marking the first new depression medicine in 30 years.
- Patients not responding to two antidepressants can access this treatment, with concession card holders paying $7.70 and general patients $31.60 per dose.
- Around 30,000 Australians are expected to benefit from this reduced cost, as many experience significant improvements in their condition.
- Patients like Alexis Hutcheon describe Spravato as a 'gamechanger,' highlighting its life-changing impact.
Insights by Ground AI
Does this summary seem wrong?
18 Articles
18 Articles
All
Left
8
Center
Right
4
Depression treatment funding breaks 30-year drought
The federal government is set to fund a new type of medicine for major depression. (Lukas Coch/AAP PHOTOS) By Samantha Lock A mind-altering medication chemically akin to ketamine will be made cheaper to improve the lives of Australians suffering from treatment-resistant depression – the first new government-backed initiative to treat the chronic mental illness in decades. The drug – which comes in the form of a nasal spray – is a chemical cousin…
·Canberra, Australia
Read Full ArticleCoverage Details
Total News Sources18
Leaning Left8Leaning Right4Center0Last UpdatedBias Distribution67% Left
Bias Distribution
- 67% of the sources lean Left
67% Left
L 67%
R 33%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
